Candesartan reduces urinary fatty acid-binding protein excretion in patients with autosomal dominant polycystic kidney disease

American Journal of the Medical Sciences

Volumn 330, Issue 4, 2005, Pages 161-165

  Nakamura, Tsukasa ^a   Sugaya, Takeshi ^b   Kawagoe, Yasuhiro ^a   Ueda, Yoshihiko ^c   Osada, Shiwori ^d   Koide, Hikaru ^c,d  

^a Shinmatsudo Central General Hospital   (Japan)

^b RIKEN KOBE INSTITUTE   (Japan)

^c DOKKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d KOTO HOSPITAL   (Japan)

Author keywords

Angiotensin II receptor antagonist; L fatty acid binding protein; Polycystic kidney disease; Renal proximal tubule

Indexed keywords

ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN HEXETIL; CREATININE; FATTY ACID; FATTY ACID BINDING PROTEIN; PLACEBO; UREA;

ADULT; ARTICLE; BLOOD PRESSURE; CHRONIC GLOMERULONEPHRITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; INTERSTITIAL NEPHRITIS; KIDNEY POLYCYSTIC DISEASE; KIDNEY PROXIMAL TUBULE; MALE; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; UREA BLOOD LEVEL;

EID: 27244452311     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-200510000-00002     Document Type: Article

References (29)

1. Gabow PA. Autosomal dominant polycystic kidney disease. N Engl J Med 1993;329:332-42.
2. Eo HS, Lee JG, Ahn C, et al. Three novel mutations of the PKD1 gene in Korean patients with autosomal dominant polycystic kidney disease. Clin Genet 2002;62:169-74.
3. van Dijk MA, Breuning MH, Duiser R, et al. No effect of enalapril on progression in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 2003;18:2314-20.
4. Remuzzi G, Ruggenenti P, Benigni A. Understanding the nature of renal disease progression. Kidney Int 1997;51:2-15.
5. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med 1998;339:1448-56.
6. Chapman AB, Johnson AM, Gabow PA, et al. Overt proteinuria and microalbuminuria in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1994;5:1349-54.
7. Nakamura T, Ushiyama C, Takahashi Y, et al. Effect of dilazep dihydrochloride on urinary albumin excretion in patients with autosomal dominant polycystic kidney disease. Nephron 2001;88:80-2.
8. Zimmerman AW, van Moerkerk HTB, Veerkamp JH. Ligand specificity and conformational stability of human fatty acid-binding proteins. Int J Biochem Cell Biol 2001;33:865-76.
9. Thomas ME, Harris KP, Walls J, et al. Fatty acids exacerbate tubulointerstitial injury in protein-overload proteinuria. Am J Physiol Renal Physiol 2002;283:F640-7.
10. Kamijo A, Kimura K, Sugaya T, et al. Urinary fatty acid-binding protein as a new clinical marker of the progression of chronic renal disease. J Lab Clin Med 2004;143:23-30.
11. Ravine D, Gibsron RN, Walker RG. Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease. Lancet 1994;343:824-7.
12. Nakamura T, Ushiyama C, Osada S, et al. Combination therapy of trandolapril and candesartan cilexetil reduces microalbuminuria and urinary endothelin-1 excretion in patients with type 2 diabetes. Clin Exp Nephrol 2002;6:135-9.
13. Nagai K, Thogersen HC. Generation of beta-globin by sequence-specific proteolysis of a hybrid protein produced in Escherichia coli. Nature 1984;309:810-2.
14. Kearney JF, Radbruch A, Liesegang B, et al. A new mouse myeloma cell line that has lost immunoglobulin expression but permits the construction of antibody-secreting hybrid cell lines. J Immunol 1979;123:1548-50.
15. Ecder T, Chapman AB, Brosnahan GM, et al. Effect of antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis 2000;35:427-32.
16. Humes HD, Nguyen VD, Cieslinski DA, et al. The role of free acids in hypoxia-induced injury to renal proximal tubule cells. Am J Physiol 1989;256:F688-96.
17. Matthys E, Patel Y, Kreisberg J, et al. Lipid alterations induced by renal ischemia: pathogenic factor in membrane damage. Kidney Int 1984;26:153-61.
18. Tomobe K, Philbrick D, Aukema H, et al. Early dietary protein restriction slows disease progression and lengthens survival in mice with polycystic kidney disease. J Am Soc Nephrol 1994;5:1355-60.
19. Ogborn M, Sareen S. Amelioration of polycystic kidney disease by modification of dietary protein intake in the rat. J Am Soc Nephrol 1995;6:1649-54.
20. Tanner GA, Potassium citrate/citric acid intake improves renal function in rats with polycystic kidney disease. J Am Soc Nephrol 1998;9:1242-8.
21. Torres V, Cowley BJ, Branden M, et al. Long-term ammonium chloride or sodium bicarbonate treatment in two models of polycystic kidney disease. Exp Nephrol 2001;9:171-80.
22. Tanner G, Vijayalakshmi K, Tanner J. Effects of potassium citrate/citric acid intake in a mouse model of polycystic kidney disease. Nephron 2000;84:270-3.
23. Navarro JF, Mora C, Muros M, et al. Effects of pentoxifylline administration on urinary N-acetyl-beta-glucosaminidase excretion in type 2 diabetic patients: a short-term prospective, randomized study. Am J Kidney Dis 2003;42:264-70.
24. Szechinski J, Wiland P. Renal proximal dysfunction based on activity of n-acetyl-beta-d-glucosaminidase in urine of patients with kidney failure. Pol Arch Med Wewnh 1997;98:536-41.
25. Chapman AB, Johnson A, Gabow PA, et al. The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease. N Engl J Med 1990;323:1091-6.
26. Ecder T, Edelstein CL, Fick G, et al. Diuretics versus angiotensin-converting enzyme inhibitors in autosomal dominant polycystic kidney disease. Am J Nephrol 2001;21:98-103.
27. Marin R, Ruilope LM, Aljama P, et al. A random comparison of fosinopril and nifedipine GITS in patients with primary renal disease. J Hypertens 2001;19:1871-6.
28. Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin- converting-Enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996;334:939-45.
29. Keith DS, Torres VE, Johnson CM, et al. Effect of sodium chloride, enalapril, and losartan on the development of polycystic kidney disease in Han:SPRD rats. Am J Kidney Dis 1994;24:491-8.